Home > Insider Trading > Filing (0000950170-23-049765)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1779308	Catriona Yale	C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	Chief Development Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-09-13	617	$50.34	46,010	No	4	S	Direct
Common Stock	Acquisiton	2023-09-21	5,000	$6.36	51,010	No	4	M	Direct
Common Stock	Disposition	2023-09-21	2,800	$47.85	48,210	No	4	S	Direct
Common Stock	Disposition	2023-09-21	2,200	$48.36	46,010	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-09-21	5,000	$0.00	5,000	$6.36

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,172		2029-01-15	No	4	M	Direct

Footnotes

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 23, 2023, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.18 to $48.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.18 to $48.57, inclusive.
The options are vested and currently exercisable.